Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Digestive Diseases and Sciences
Erschienen in: Digestive Diseases and Sciences 10/2021

13.11.2020 | Original Article

Inflammation, Tumoral Markers and Interleukin-17, -10, and -6 Profiles in Pancreatic Adenocarcinoma and Chronic Pancreatitis

verfasst von: Alina Tanţău, Daniel-Corneliu Leucuţa, Marcel Tanţău, Emil Boţan, Roxana Zaharie, Alina Mândruţiu, Ionuţ-Ciprian Tomuleasa

Erschienen in: Digestive Diseases and Sciences | Ausgabe 10/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Interleukin profiles can be used as biochemical markers regarding the early diagnosis of pancreatic cancer.

Aims

To assess CRP, CA 19-9, CEA levels, and interleukin-6, -10, and -17 profiles in pancreatic ductal adenocarcinoma, chronic pancreatitis was compared with a control group, and the correlation with pancreatic cancer survival.

Methods

A total of 87 patients were prospective divided in pancreatic cancer (n = 53), chronic pancreatitis (n = 22) ,and control group (n = 12). The diagnosis of PDAC was made histologically. The diagnosis of chronic pancreatitis was based on medical history, imaging methods, and endoscopic ultrasound. Systemic concentrations of interleukins were measured using ELISA kits. The patients were followed at 1, 3, and 6 months.

Results

CRP, CA 19-9, and CEA were higher in the pancreatic cancer group (p < 0.001). Interleukin-10 was significantly higher in the pancreatic cancer and chronic pancreatitis groups (p < 0.001). Interleukin-17 was statistically higher in the pancreatic cancer group (p < 0.0001). The cut-off of interleukin-17 of 0.273 had a sensitivity of 90.9 and a specificity of 80.9 with a curve under ROC of 0.80 in order to differentiate between pancreatic cancer and chronic pancreatitis. The serum levels of interleukins are not correlated with the stage of the disease. CRP, CA 19-9, CEA, and interleukin-6, -10, and -17 were lower in patients with survival more than 6 months.

Conclusions

We detected high levels of interleukin-6, -10, and -17 in chronic pancreatitis and pancreatic cancer. Serum interleukin-17 levels can discriminate between pancreatic cancer and chronic pancreatitis. The prognostic role of interleukins needs to be established.
Literatur
1.
Wu HH, Hwang-Verslues WW, Lee WH, et al. Targeting IL-17B–IL-17RB signaling with an anti–IL-17RB antibody blocks pancreatic cancer metastasis by silencing multiple chemokines. J Exp Med. 2015;212:333–349.PubMedCentralCrossRefPubMed
2.
3.
Babic A, Schnure N, Neupane NP, et al. Plasma inflammatory cytokines and survival of pancreatic cancer patients. Clin Transl Gastroenterol. 2018;9:145.PubMedCentralCrossRefPubMed
4.
Greer JB, Whitcomb DC. Inflammation and pancreatic cancer: an evidence-based review. CurrOpinPharmacol. 2009;9:411–418.
5.
6.
Roshani R, McCarthy F, Hagemann T. Inflammatory cytokines in human pancreatic cancer. Cancer Lett. 2014;345:157–163.CrossRefPubMed
7.
Yako YY, Kruger D, Smith M, Brand M. Cytokines as biomarkers of pancreatic ductal adenocarcinoma: a systematic review. PLoS ONE. 2016;11:e0154016.PubMedCentralCrossRefPubMed
8.
McAllister F, Bailey JM, Alsina J, et al. Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. Cancer Cell. 2014;25:621–637.PubMedCentralCrossRefPubMed
9.
10.
Ghassem-Zadeh S, Gaida MM, Szanyi S, Acha-Orbea H, Frossard JL, Hinz U. Distinct pathophysiological cytokine profiles for discrimination between autoimmune pancreatitis, chronic pancreatitis, and pancreatic ductal adenocarcinoma. J Transl Med. 2017;15:126.PubMedCentralCrossRefPubMed
11.
12.
American Joint Committee on Cancer. Exocrine pancreas. In: Amin MB, Edge S, Greene F, et al., eds. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017:337–350.
13.
Bellone G, Smirne C, Mauri FA, et al. Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival. Cancer Immunol Immunother. 2006;55:684–698.CrossRefPubMed
14.
Ebrahimi B, Tucker SL, Li D, Abbruzzese JL, Kurzrock R. Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer. 2004;101:2727–2736.CrossRefPubMed
15.
Falconer JS, Fearon KC, Ross JA, et al. Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer. 1995;75:2077–2082.CrossRefPubMed
16.
Mroczko B, Groblewska M, Gryko M, Kedra B, Szmitkowski M. Diagnostic usefulness of serum interleukin 6 (IL-6) and C-reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis. J Clin Lab Anal. 2010;24:256–261.PubMedCentralCrossRefPubMed
17.
Szkandera J, Stotz M, Absenger G, et al. Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients. Br J Cancer. 2014;110:183–188.CrossRefPubMed
18.
Tingstedt B, Johansson P, Andersson B, Andersson R. Predictive factors in pancreatic ductal adenocarcinoma: role of the inflammatory response. Scand J Gastroenterol. 2006;42:754–759.CrossRef
19.
Papadoniou N, Kosmas C, Gennatas K, Polyzos A, Mouratidou D, Skopelitis E. Prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis. Anticancer Res. 2008;28:543–550.PubMed
20.
21.
Bachmann J, Heiligensetzer M, Krakowski-Roosen H, Büchler MW, Friess H, Martignoni ME. Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg. 2008;12:1193–1201.CrossRefPubMed
22.
Mews P, Phillips P, Fahmy R, et al. Pancreatic stellate cells respond to inflammatory cytokines: potential role in chronic pancreatitis. Gut. 2002;50:535–541.PubMedCentralCrossRefPubMed
23.
Ireland L, Santos A, Ahmed MS, et al. Chemoresistance in pancreatic cancer is driven by stroma-derived insulin-like growth factors. Cancer Res. 2016;76:6851–6863.PubMedCentralCrossRefPubMed
24.
Daftarian PM, Kumar A, Kryworuchko M, Diaz-Mitoma F. IL-10 production is enhanced in human T cells by IL-12 and IL-6 and in monocytes by tumor necrosis factor-alpha. J Immunol. 1996;157:12–20.PubMed
25.
Demols A, Van Laethem JL, Quertinmont E, et al. Endogenous interleukin-10 modulates fibrosis and regeneration in experimental chronic pancreatitis. Am J Physiol Gastrointest Liver Physiol. 2002;282:G1105–G1112.CrossRefPubMed
26.
Dima SO, Tanase C, Albulescu R, et al. An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma. Pancreas. 2012;41:1001–1007.CrossRefPubMed
27.
Zhang P, Zou M, Wen X, et al. Development of serum parameters panels for the early detection of pancreatic cancer. Int J Cancer. 2014;134:2646–2665.CrossRefPubMed
28.
Plate JM, Shott S, Harris JE. Immunoregulation in pancreatic cancer patients. Cancer Immunol Immunother. 1999;48:270–279.CrossRefPubMed
29.
Breitbart W, Rosenfeld B, Tobias K, et al. Depression, cytokines, and pancreatic cancer. Psychooncology. 2014;23:339–345.CrossRefPubMed
30.
Bellone G, Novarino A, Vizio B, et al. Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy. Int J Oncol. 2009;34:1701–1715.CrossRefPubMed
31.
Bang S, Kim HS, Choo YS, Park SW, Chung JB, Song SY. Differences in immune cells engaged in cell-mediated immunity after chemotherapy for far advanced pancreatic cancer. Pancreas. 2006;32:29–36.CrossRefPubMed
32.
von Bernstorff W, Voss M, Freichel S, et al Systemic and local immunosuppression in pancreatic cancer patients. Clinical Cancer Res. 2001;7:925s–932s.
33.
Wenger FA, Jacobi CA, Zieren J, Docke W, Volk HD, Muller JM. Tumor size and lymph-node status in pancreatic carcinoma—is there a correlation to the preoperative immune function? Langenbecks Arch Surg. 1999;384:473–478.CrossRefPubMed
34.
Marchesi F, Grizzi F, Laghi L, Mantovani A, Allavena P. Molecular mechanisms of pancreatic cancer dissemination: the role of the chemokine system. Curr Pharm Des. 2012;18:2432–2438.CrossRefPubMed
35.
36.
Karabulut S, Afsar CU, Karabulut M, et al. Evaluation of serum interleukin-17 (IL-17) levels as a diagnostic marker in pancreatic adenocarcinoma. J Gastrointest Cancer. 2016;47:47–54.CrossRefPubMed
37.
Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33:266–270.CrossRefPubMed
38.
Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24:5313–5327.CrossRefPubMed
39.
Barton JG, Bois JP, Sarr MG, et al. Predictive and prognostic value of CA 19-9 in resected pancreatic adenocarcinoma. J Gastrointest Surg. 2009;13:2050–2058.CrossRefPubMed
40.
Reni M, Cereda S, Balzano G, et al. Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer. 2009;115:2630–2639.CrossRefPubMed
41.
Canto MI, Goggins M, Hruban RH, et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol. 2006;4:766–781.CrossRefPubMed
42.
Canto MI, Goggins M, Yeo CJ, et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol. 2004;2:606–621.CrossRefPubMed
43.
Chu D, Kohlmann W, Adler DG. Identification and screening of individuals at increased risk for pancreatic cancer with emphasis on known environmental and genetic factors and hereditary syndromes. JOP. 2010;11:203–212.PubMed
44.
Klapman J, Malafa MP. Early detection of pancreatic cancer: why, who, and how to screen. Cancer Control. 2008;15:280–287.CrossRefPubMed
45.
Langer P, Kann PH, Fendrich V, et al. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut. 2009;58:1410–1418.CrossRefPubMed
46.
Ludwig E, Olson SH, Bayuga S, et al. Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol. 2011;106:946–954.PubMedCentralCrossRefPubMed
47.
Poley JW, Kluijt I, Gouma DJ, et al. The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol. 2009;104:2175–2181.CrossRefPubMed
48.
Verna EC, Hwang C, Stevens PD, et al. Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res. 2010;16:5028–5037.CrossRefPubMed
49.
Shaw VE, Lane B, Jenkinson C, et al. Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease. Mol Cancer. 2014;13:114.PubMedCentralCrossRefPubMed
50.
Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-del Castillo C, Warshaw AL. Perioperative CA 19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinomas. J Clin Oncol. 2006;24:2897–2902.CrossRefPubMed
51.
Berger AC, Garcia M, Hoffmann JP, et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol. 2008;26:5918–5922.PubMedCentralCrossRefPubMed
52.
Yixiang M, Min T, Xiaoyan J, et al. Effect of diabetes mellitus on survival in patients with pancreatic cancer: a systematic review and meta-analysis. Sci Rep. 2015;5:17102.CrossRef
53.
Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA. 1995;273:1605–1609.CrossRefPubMed
54.
Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies Br J Cancer.. 2005;92:2076–2083.PubMedCentralCrossRefPubMed
55.
56.
Chari ST, Kari LC, Rabe G, Ransom J, de Andrade M, Petersen MG. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology. 2005;129:504–511.CrossRefPubMed
57.
Gupta S, Vittinghoff E, Bertenthal D. New-onset diabetes and pancreatic cancer. Clin Gastroenterol Hepatol. 2006;4:1366–1372.CrossRefPubMed
58.
Metadaten
Titel
Inflammation, Tumoral Markers and Interleukin-17, -10, and -6 Profiles in Pancreatic Adenocarcinoma and Chronic Pancreatitis
verfasst von
Alina Tanţău
Daniel-Corneliu Leucuţa
Marcel Tanţău
Emil Boţan
Roxana Zaharie
Alina Mândruţiu
Ionuţ-Ciprian Tomuleasa
Publikationsdatum
13.11.2020
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 10/2021
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-020-06700-w

Weitere Artikel der Ausgabe 10/2021

Digestive Diseases and Sciences 10/2021 Zur Ausgabe

Original Article

Impact of COVID-19 Pandemic on Training: Global Perceptions of Gastroenterology and Hepatology Fellows in the USA

Original Article

DNA Damage-Regulated Autophagy Modulator 1 (DRAM1) Mediates Autophagy and Apoptosis of Intestinal Epithelial Cells in Inflammatory Bowel Disease

DDS–SIRC COOPERATIVE CONFERENCES

Gas in the Portal Vein: An Emergency or Just Hot Air?

Original Article

HIPK3 Circular RNA Promotes Metastases of HCC Through Sponging miR-338-3p to Induce ZEB2 Expression

Original Article

High-Fat Diet Induces Disruption of the Tight Junction-Mediated Paracellular Barrier in the Proximal Small Intestine Before the Onset of Type 2 Diabetes and Endotoxemia

Original Article

Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise